SK bioscience

본문바로가기

사이트맵 닫기

PR

SK bioscience company news updates

Press releases

SK bioscience’s COVID-19 Vaccine ‘SKYCovione™’ Shows Cross-Neutralizing Activity Against Omicron Variant BA.1 as Booster Shot

2022.07.13
SK bioscience and GSK Announce Biologics License Application Approval of SKYCovione™ in Republic of Korea

2022.06.29
SK bioscience Marks Successful Completion of Global Forum to Prepare the Next Pandemic

2022.06.28
SK bioscience and the Bill & Melinda Gates Foundation Agreed to Strengthen Partnership

2022.05.17
SK bioscience and GSK’s Adjuvanted COVID-19 Vaccine Candidate Meets Coprimary Objectives in a Phase III Study; Biologics License Application Submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea

2022.04.29
SK bioscience Reports Positive Phase III Immunogenicity Results of Its Adjuvanted Covid-19 Vaccine Clinical Trial of COVID-19 Vaccine, AS03-adjuvanted

2022.04.25
SK bioscience Initiates Clinical Development of Antiviral Nasal Spray for Prevention of COVID-19

2022.04.13
SK bioscience Submits Post Approval Change Application of Protein-Based COVID-19 Vaccine for Adolescent Authorization to KMFDS

2022. 04. 07
SK bioscience Submits Rolling Review of Nuvaxovid for Adolescent Authorization to KMFDS

2022.03.23
SK bioscience Announces Commencement of Booster Trial of Adjuvanted COVID-19 Vaccine Candidate ‘GBP510(AS03)’ in South Korea

2022. 03. 22